- Conditions
- HIV Infections, ART, Noncompliance, Patient
- Interventions
- The Accelerate model of care, bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg
- Other · Drug
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 4
- States / cities
- Columbia, Missouri • Kansas City, Missouri • Springfield, Missouri + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–34
of 34
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV-1 Infection
- Interventions
- B/F/TAF, NRTIs, Third Agent
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 496 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 82
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 53 more
- Conditions
- HIV-1 Infection
- Interventions
- ISL, LEN, B/F/TAF, ISL/LEN FDC
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 44
- States / cities
- Beverly Hills, California • Los Angeles, California • Newport Beach, California + 33 more
- Conditions
- HIV-1 Infection
- Interventions
- Islatravir, Ulonivirine, BIC/FTC/TAF, Placebo to ISL, Placebo to Ulonivirine, Placebo to BIC/FTC/TAF
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Los Angeles, California • Ft. Pierce, Florida + 7 more
- Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Interventions
- ISL, ULO, BIC/FTC/TAF, Placebo for BIC/FTC/TAF, Placebo to ISL/ULO, ISL/ULO
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 570 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 24
- States / cities
- Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 20 more
- Conditions
- HIV-1 Infection
- Interventions
- B/F/TAF (Adult Strength), B/F/TAF (Low Dose), B/F/TAF (TOS)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 10
- States / cities
- Washington D.C., District of Columbia • Ft. Pierce, Florida • Gainesville, Florida + 7 more
- Conditions
- HIV -1 Infection, HIV (Human Immunodeficiency Virus), HIV, HIV 1 Infection
- Interventions
- Bictegravir, emtricitabine, and tenofovir alafenamide
- Drug
- Lead sponsor
- CAN Community Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 10
- States / cities
- Clearwater, Florida • Ft. Pierce, Florida • Jacksonville, Florida + 6 more
- Conditions
- HIV-1-infection
- Interventions
- lepetegravir, lenacapavir pacfosacil, Bictegravir/emtricitabine/tenofovir alafenamide, lepetegravir/lenacapavir pacfosacil FDC, Placebo to Match BVY, Placebo to Match GS1720/GS-4182 FDC
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Torrance, California • West Hollywood, California + 17 more
- Conditions
- HIV Infection
- Interventions
- DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to FDC DOR/ISL
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 643 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 24 more
- Conditions
- HIV-1-infection
- Interventions
- B/F/TAF
- Drug
- Lead sponsor
- Tulika Singh, MD
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Palm Springs, California